5 News & Press Releases found
AB2 Bio Ltd. News
-
AB2 Bio expands Phase 3 trial of Tadekinig alfa in monogenic HLH
AB2 Bio Ltd, a Swiss advanced clinical-stage biotech company, specialized in developing innovative therapies for the treatment of severe systemic autoinflammatory diseases including rare diseases with high unmet medical needs, announces the ...
-
AB2 Bio Appoints Dr Djordje Filipovic as Chief Commercial Officer
Will drive commercial strategy and execution of Tadekinig alfa, currently in Phase 3 Joins AB2 Bio from Novartis and has extensive commercial and strategic experience AB2 Bio Ltd., a Phase 3 clinical-stage biotech company developing innovative ...
-
AB2 Bio and WuXi Biologics Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa
Tadekinig alfa is a novel IL-18 binding protein in pivotal Phase 3 testing for orphan disease IL-18 driven monogenic Hemophagocytic Lymphohistiocytosis (HLH) WuXi Biologics to undertake commercial scale manufacturing to support U.S. market launch ...
-
AB2 Bio appoints Michael Soldan CEO
AB2 Bio Ltd, a Swiss advanced clinical-stage biotech company, specialized in developing innovative therapies for the treatment of severe systemic autoinflammatory diseases including rare diseases with high unmet medical needs, announces the ...
-
AB2 Bio announces readiness for recruitment in pivotal Phase 3 trial of Tadekinig alfa, a novel human recombinant interleukin-18 binding protein, in children with genetic diagnosis of NLRC4-MAS mutation or XIAP deficiency, with amended design in the U.S.
AB2 Bio Ltd, a Swiss advanced clinical-stage biotech company, specialized in developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, announced today that a single-arm open label design with a randomized ...